Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

Emergency medical services bring a 72-year-old male resident of a skilled nursing facility to the acute care setting following a two-day history of worsening confusion, fever, and purulent sputum production. Upon triage, he appears lethargic and is in mild respiratory distress. Vital signs reveal a temperature of 38.9°C (102.0°F), a blood pressure of 88/56 mmHg, a heart rate of 112/min, and a respiratory rate of 26/min. Room air pulse oximetry indicates an oxygen saturation of 89%. Auscultation of the lungs demonstrates dense, coarse crackles localized to the right lower lung base. A portable chest radiograph confirms a new dense consolidation in the right lower lobe. A review of his electronic medical record reveals a prior ischemic stroke complicated by oropharyngeal dysphagia. Notably, he was discharged from the hospital one month ago after being treated for complicated pyelonephritis with a 10-day course of intravenous levofloxacin. Blood and sputum cultures are sent to the laboratory.

Which of the following antimicrobial agents should be included in his initial empiric pharmacologic regimen? (Select all that apply)

  1. VancomycinCevap
  2. CefepimeCevap
  3. C
    Ceftriaxone
  4. D
    Levofloxacin
  5. E
    Metronidazole

Cevap

Vancomycin and cefepime
The correct combination includes vancomycin and cefepime. This patient presents with severe pneumonia and has specific risk factors for resistant pathogens, namely a recent hospitalization and receipt of intravenous antibiotics within the past 90 days. Therefore, empiric therapy must be broadened beyond standard community-acquired regimens to cover Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Vancomycin provides the necessary MRSA coverage, while cefepime serves as an appropriate anti-pseudomonal beta-lactam.

Adım Adım Çözüm

1
Assess the severity of the pneumonia and identify risk factors for resistant organisms.
The patient has severe pneumonia with risk factors for MRSA and Pseudomonas aeruginosa due to a recent hospitalization and receipt of intravenous antibiotics in the last 90 days.
Identifying risk factors for resistant pathogens dictates the need to broaden empiric antimicrobial coverage beyond standard community-acquired pneumonia regimens.
2
Select appropriate empiric antimicrobial agents based on the identified risk factors.
Select an anti-MRSA agent (vancomycin) and an anti-pseudomonal beta-lactam (cefepime).
Standard community-acquired regimens are insufficient for this patient; dual coverage targeting both MRSA and Pseudomonas is required to optimize survival.

Anahtar Kavram

Patients presenting with severe pneumonia who have specific risk factors (e.g., recent hospitalization and intravenous antibiotic use within the past 90 days) require empiric broad-spectrum coverage targeting both MRSA and Pseudomonas aeruginosa.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru